{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:06:53Z","timestamp":1773659213334,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,6,3]],"date-time":"2017-06-03T00:00:00Z","timestamp":1496448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2017,6,3]],"date-time":"2017-06-03T00:00:00Z","timestamp":1496448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Goverment of Gujarat","award":["BH-12404"],"award-info":[{"award-number":["BH-12404"]}]},{"name":"Zydus Research Centre"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Virol"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s00705-017-3411-4","type":"journal-article","created":{"date-parts":[[2017,6,3]],"date-time":"2017-06-03T14:54:57Z","timestamp":1496501697000},"page":"2705-2713","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Evaluation of the oncolytic potential of R2B Mukteshwar vaccine strain of Newcastle disease virus (NDV) in a colon cancer cell line (SW-620)"],"prefix":"10.1007","volume":"162","author":[{"given":"Kishan K.","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irsadullakhan H.","family":"Kalyani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jogeswar","family":"Mohapatra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satish D.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dharmesh R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priti D.","family":"Vihol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhijit","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinesh R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhavesh","family":"Vyas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,3]]},"reference":[{"key":"3411_CR1","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.3390\/v7072811","volume":"7","author":"M Adelfinger","year":"2015","unstructured":"Adelfinger M, Bessler S, Frentzen A, Cecil A, Langbein-Laugwitz J, Gentschev I, Szalay AA (2015) Preclinical testing oncolytic vaccinia virus strain GLV-5b451 expressing an anti-VEGF single-chain antibody for canine cancer therapy. Viruses 7:4075\u20134092","journal-title":"Viruses"},{"key":"3411_CR2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3923\/ijps.2004.153.156","volume":"3","author":"T Ahamed","year":"2004","unstructured":"Ahamed T, Hossain KM, Billah MM, Islam KMD, Ahasan MM, Islam ME (2004) Adaptation of Newcastle disease virus (NDV) on Vero cell line. Int J Poultry Sc 3:153\u2013156","journal-title":"Int J Poultry Sc"},{"key":"3411_CR3","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/mt.2009.231","volume":"18","author":"J Altomonte","year":"2010","unstructured":"Altomonte J, Marozin S, Schmid RM, Ebert O (2010) Engineered Newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma. Mol Ther 18:275\u2013284","journal-title":"Mol Ther"},{"key":"3411_CR4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2174\/1874226200902010079","volume":"2","author":"JE Beliz\u00e1rio","year":"2009","unstructured":"Beliz\u00e1rio JE (2009) Immunodeficient mouse models: an overview. Open Immunol J 2:79\u201385","journal-title":"Open Immunol J"},{"key":"3411_CR5","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.3390\/v7062756","volume":"7","author":"P Buijs","year":"2015","unstructured":"Buijs P, van Nieuwkoop S, Vaes V, Fouchier R, van Eijck C, van den Hoogen B (2015) Recombinant immunomodulating lentogenic or mesogenic oncolytic Newcastle disease virus for treatment of pancreatic adenocarcinoma. Viruses 7:2980\u20132998","journal-title":"Viruses"},{"key":"3411_CR6","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1743-422X-11-84","volume":"11","author":"Z Chai","year":"2014","unstructured":"Chai Z, Zhang P, Fu F, Zhang X, Liu Y, Hu L, Li X (2014) Oncolytic therapy of a recombinant Newcastle disease virus D90 strain for lung cancer. J Virol 11:84\u201392","journal-title":"J Virol"},{"key":"3411_CR7","first-page":"63","volume":"4","author":"JJ Cody","year":"2015","unstructured":"Cody JJ, Hurst DR (2015) Promising oncolytic agents for metastatic breast cancer treatment. Oncol Virotherap 4:63\u201373","journal-title":"Oncol Virotherap"},{"key":"3411_CR8","doi-asserted-by":"publisher","first-page":"e98869","DOI":"10.1371\/journal.pone.0098869","volume":"9","author":"S Dey","year":"2014","unstructured":"Dey S, Chellappa MM, Gaikwad S, Kataria JM, Vakharia VN (2014) Genotype characterization of commonly used Newcastle Disease Virus vaccine strains of India. PLoS One 9:e98869. doi:10.1371\/journal.pone.0098869","journal-title":"PLoS One"},{"key":"3411_CR9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1479-5876-11-79","volume":"11","author":"K Ehrig","year":"2013","unstructured":"Ehrig K, Kilinc MO, Chen NG, Stritzker J, Buckel L, Zhang Q, Szalay AA (2013) Growth inhibition of different human colorectal cancer xenografts after a single intravenous injection of oncolytic vaccinia virus GLV-1h68. J Transl Med 11:79. doi:10.1186\/1479-5876-11-79","journal-title":"J Transl Med"},{"key":"3411_CR10","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1128\/JVI.01553-09","volume":"84","author":"S Elankumaran","year":"2010","unstructured":"Elankumaran S, Chavan V, Qiao D, Shobana R, Moorkanat G, Biswas M, Samal SK (2010) Type I interferon-sensitive recombinant Newcastle disease virus for oncolytic virotherapy. J Virol 84:3835\u20133844","journal-title":"J Virol"},{"key":"3411_CR11","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ymthe.2005.08.016","volume":"13","author":"AI Freeman","year":"2006","unstructured":"Freeman AI, Zakay-Rones Z, Gomori JM, Linetsky E, Rasooly L, Greenbaum E, Rozenman-Yair S, Panet A, Libson E, Irving CS, Galun E, Siegal T (2006) Phase I\/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 13:221\u2013228","journal-title":"Mol Ther"},{"key":"3411_CR12","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/gt.2009.161","volume":"17","author":"F Galivo","year":"2010","unstructured":"Galivo F, Diaz RM, Wongthida P, Thompson J, Kottke T, Barber G, Melcher A, Vile R (2010) Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma. Gene Ther 17:158\u2013170","journal-title":"Gene Ther"},{"key":"3411_CR13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.virusres.2014.02.016","volume":"184","author":"K Ganar","year":"2014","unstructured":"Ganar K, Das M, Sinha S, Kumar S (2014) Newcastle disease virus: Current status and our understanding. Virus Res 184:71\u201381","journal-title":"Virus Res"},{"key":"3411_CR14","doi-asserted-by":"crossref","unstructured":"Gentschev I, Adelfinger M, Josupiet R, Ruldoph S, Ehrig K, Donat U, Weibel S, Chen NG, Yu YA, Zhang Q, Heisig M, Thamm D, Stritzker J, MacNeill A, Szalay AA (2012) Preclinical evaluation of oncolytic vaccinia virus for therapy of canine soft tissue sarcoma. PLoS One. 7:e37239 (Available from http:\/\/journals.plos.org\/plosone\/article\/citation?id=10.1371\/journal.pone.0037239)","DOI":"10.1371\/journal.pone.0037239"},{"key":"3411_CR15","doi-asserted-by":"publisher","unstructured":"Gentschev I, Ehrig K, Donat U, Hess M, Rudolph S, Chen N, Weibel S, Chen NG, Yu YA, Zhang Q, Heisig M, Thamm D, Stritzker J, MacNeill A, Szalay AA (2010) Significant growth inhibition of canine\u00a0mammary\u00a0carcinoma xenografts following treatment with oncolytic vaccinia virus GLV-1h68. J Oncol. doi:10.1155\/2010\/736907). (http:\/\/www.hindawi.com\/journals\/jo\/2010\/736907\/)","DOI":"10.1155\/2010\/736907"},{"key":"3411_CR16","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.3390\/v6052122","volume":"6","author":"I Gentschev","year":"2014","unstructured":"Gentschev I, Patil SS, Petrov I, Cappello J, Adelfinger M, Szalay AA (2014) Oncolytic virotherapy of canine and feline cancer. Viruses 6:2122\u20132137","journal-title":"Viruses"},{"key":"3411_CR17","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1099\/vir.0.046672-0","volume":"93","author":"E Hastie","year":"2012","unstructured":"Hastie E, Grdzelishvili VZ (2012) Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. J Gen Virol 93:2529\u20132545","journal-title":"J Gen Virol"},{"key":"3411_CR18","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1158\/1078-0432.CCR-06-1817","volume":"13","author":"SJ Hotte","year":"2007","unstructured":"Hotte SJ, Lorence RM, Hirte HW, Polawski SR, Bamat MK, O\u2019Neil JD, Roberts MS, Groene WS, Major PP (2007) An optimized clinical regimen for the oncolytic virus PV701. Clin Cancer Res 13:977\u2013985","journal-title":"Clin Cancer Res"},{"key":"3411_CR19","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/S1525-0016(03)00204-1","volume":"8","author":"TG Huang","year":"2003","unstructured":"Huang TG, Ebert O, Shinozaki K, Gracia-Sastre A, Woo SLC (2003) Oncolysis of hepatic metastasis of colorectal cancer by recombinant vesicular stomatitis virus in immune \u2013competent mice. Mole Ther 8:434\u2013440","journal-title":"Mole Ther"},{"key":"3411_CR20","doi-asserted-by":"crossref","unstructured":"Iikow CS, Swift SL, Bell JC, Diallo JS (2014) From scourage to cure: Tumour selective viral pathogenesis as a new strategy against cancer. PloS Pathog 10:e1003836 (http:\/\/journals.plos.org\/plospathogens\/article?id=10.1371\/journal.ppat.1003836)","DOI":"10.1371\/journal.ppat.1003836"},{"key":"3411_CR21","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1038\/mt.2014.34","volume":"22","author":"V Janelle","year":"2013","unstructured":"Janelle V, Langlois M, Lapierre P, Charpentier T, Poliquin L, Lamarre A (2013) The strength of the T cell response against a surrogate tumor antigen induced by oncolytic VSV therapy does not correlate with tumor control. Mole Ther 22:1198\u20131210","journal-title":"Mole Ther"},{"key":"3411_CR22","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1096\/fasebj.13.11.1325","volume":"13","author":"DA Kooby","year":"1999","unstructured":"Kooby DA, Carew JF, Halterman M, Mack W, Jonathan E, Bertino JR, Blumgart LH, Federoff HJ, Fong Y (1999) Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEBJ 13:1325\u20131334","journal-title":"FASEBJ"},{"key":"3411_CR23","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/0166-0934(88)90132-2","volume":"20","author":"B Kournikakis","year":"1988","unstructured":"Kournikakis B, Fildes J (1988) Titration of avirulent Newcastle disease virus by plaque assay method. J Virol Methods 20:185\u2013193","journal-title":"J Virol Methods"},{"key":"3411_CR24","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1007\/s12010-012-9700-1","volume":"167","author":"R Kumar","year":"2012","unstructured":"Kumar R, Tiwari AK, Chaturvedi U, Kumar GR, Sahoo AP, Rajmani RS, Saxena L, Saxena S, Tiwari S, Kumar S (2012) Velogenic Newcastle disease virus as an oncolytic virotherapeutics: in vitro characterization. Appl Biochem Biotechnol 167:2005\u20132022","journal-title":"Appl Biochem Biotechnol"},{"key":"3411_CR25","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/cgt.2015.35","volume":"22","author":"U Kumar","year":"2015","unstructured":"Kumar U, Kumar S (2015) Molecular characterization of an apoptotic strain of Newcastle disease virus isolated from an outbreak in India. Can Gene Ther 22:402\u2013409","journal-title":"Can Gene Ther"},{"key":"3411_CR26","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/718710","author":"HY Lam","year":"2011","unstructured":"Lam HY, Yeap SK, Rasoli M, Omar AR, Yusouff K, Suraini AA (2011) Safety and clinical uses of Newcastle disease virus in cancer therapy. J Biomed Biotechnol. doi:10.1155\/2011\/718710","journal-title":"J Biomed Biotechnol"},{"key":"3411_CR27","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1158\/1078-0432.CCR-05-2038","volume":"12","author":"SA Laurie","year":"2006","unstructured":"Laurie SA, Bell JC, Atkins HL, Roach J, Bamat MK, O\u2019Neil JD, Roberts MS, Groene WS, Lorence RM (2006) A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization. Clin Cancer Res 12:2555\u20132562","journal-title":"Clin Cancer Res"},{"key":"3411_CR28","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1002\/hed.21609","volume":"33","author":"P Li","year":"2011","unstructured":"Li P, Chen CH, Li S, Givi B, Yu Z, Zamarin D, Palese P, Fong Y, Wong RJ (2011) Therapeutic effects of a fusogenic Newcastle disease virus in treating head and neck cancer. Head Neck 33:1394\u20131399","journal-title":"Head Neck"},{"key":"3411_CR29","first-page":"6017","volume":"54","author":"RM Lorence","year":"1994","unstructured":"Lorence RM, Katubig BB, Reichard KW, Reyes HM, Phuangsab A, Sassetti MD, Walter RJ, Peeples ME (1994) Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Res 54:6017\u20136021","journal-title":"Cancer Res"},{"key":"3411_CR30","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1093\/jnci\/86.16.1228","volume":"86","author":"RM Lorence","year":"1994","unstructured":"Lorence RM, Reichard KW, Katubig BB, Reyes HM, Phuangsab A, Mitchell BR, Cascino CJ, Walter RJ, Peeples ME (1994) Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. J Natl Cancer Inst 86:1228\u20131233","journal-title":"J Natl Cancer Inst"},{"key":"3411_CR31","doi-asserted-by":"publisher","first-page":"15011","DOI":"10.1038\/mto.2015.11","volume":"2","author":"OV Maveeva","year":"2015","unstructured":"Maveeva OV, Guo ZS, Shabalina SA, Chumakov PM (2015) Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency. Mole Ther Oncolytics 2:15011. doi:10.1038\/mto.2015.11","journal-title":"Mole Ther Oncolytics"},{"key":"3411_CR32","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/sj.cgt.7700133","volume":"7","author":"S Mukherjee","year":"2000","unstructured":"Mukherjee S, Haenel T, Himbeck R, Scott B, Ramshaw I, Lake RA, Harnett G, Phillips P, Morey S, Smith D, Davidson JA, Musk AW, Robinson B (2000) Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation. Cancer Gene Ther 7:663\u2013670","journal-title":"Cancer Gene Ther"},{"key":"3411_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-3","author":"SS Patil","year":"2012","unstructured":"Patil SS, Gentschev I, Noite I, Oglive G, Szalaly AA (2012) Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients. J Trans Med. doi:10.1186\/1479-5876-10-3","journal-title":"J Trans Med"},{"key":"3411_CR34","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1200\/JCO.2002.08.042","volume":"20","author":"AL Pecora","year":"2002","unstructured":"Pecora AL, Rizvi N, Cohen GI, Meropol NJ, Sterman D, Marshall JL, Goldberg S, O\u2019Neil JD, Groene WS, Roberts S, Rabin H, Bamat MK, Lorence RM (2002) Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 20:2251\u20132266","journal-title":"J Clin Oncol"},{"key":"3411_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0304-3835(01)00617-6","volume":"172","author":"A Phuangsab","year":"2001","unstructured":"Phuangsab A, Lorence RM, Reichard KW, Peeples ME, Walter RJ (2001) Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration. Cancer Lett 172:27\u201336","journal-title":"Cancer Lett"},{"key":"3411_CR36","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/0022-4804(92)90310-V","volume":"52","author":"KW Reichard","year":"1992","unstructured":"Reichard KW, Lorance RM, Cascino CJ, Peeples ME, Waller RJ, Fernando MB, Reyes HM, Greager JA (1992) Newcastle disease virus selectively kills human tumor cells. J Surg Res 52:448\u2013453","journal-title":"J Surg Res"},{"key":"3411_CR37","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1158\/1535-7163.MCT-10-0090","volume":"9","author":"GR Silberhumer","year":"2010","unstructured":"Silberhumer GR, Brader P, Wong J, Serganova IS, G\u00f6nen M, Gonzalez SJ, Blasberg R, Zamarin D, Fong Y (2010) Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma. Mol Cancer Ther 9:2761\u20132769","journal-title":"Mol Cancer Ther"},{"key":"3411_CR38","first-page":"9","volume":"34","author":"H Singh","year":"2013","unstructured":"Singh H, Jadon NS, Tiwari AK, Pandey P (2013) Apoptotic effect of VP3 gene of chicken anaemia virus on HELA cells. Ind J Vet Surg 34:9\u201312","journal-title":"Ind J Vet Surg"},{"key":"3411_CR39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/biomedicines4030016","volume":"4","author":"V Schirrmacher","year":"2016","unstructured":"Schirrmacher V (2016) Fifty years of clinical application of Newcastle disease virus: time to celebrate! Biomedicines 4:16. doi:10.3390\/biomedicines4030016","journal-title":"Biomedicines"},{"key":"3411_CR40","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.2460\/javma.2003.222.1534","volume":"222","author":"DE Swayne","year":"2003","unstructured":"Swayne DE, King DJ (2003) Avian influenza and Newcastle disease. J Am Vet Med Assoc 222:1534\u20131540","journal-title":"J Am Vet Med Assoc"},{"key":"3411_CR41","first-page":"49","volume":"4","author":"S Tayeb","year":"2015","unstructured":"Tayeb S, Zakay-Rones Z, Panet A (2015) Therapeutic potential of oncolytic Newcastle disease virus: a critical review. Oncol Virotherap 4:49\u201362","journal-title":"Oncol Virotherap"},{"key":"3411_CR42","first-page":"1","volume-title":"Manual of diagnostic tests and vaccines for terrestrial animals","author":"The world organization for animal health","year":"2012","unstructured":"The world organization for animal health (2012) Newcastle disease. Manual of diagnostic tests and vaccines for terrestrial animals. OIE, Paris, pp 1\u201319"},{"key":"3411_CR43","doi-asserted-by":"publisher","first-page":"8285","DOI":"10.1158\/0008-5472.CAN-07-1025","volume":"67","author":"A Vigil","year":"2007","unstructured":"Vigil A, Martinez O, Chua MA, Xiao S, Cros JF, Mart\u00ednez-Sobrido L, Woo SL, Grarcia-Sastre A (2007) Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res 67:8285\u20138292","journal-title":"Cancer Res"},{"key":"3411_CR44","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1089\/hum.2011.207","volume":"23","author":"D Wei","year":"2012","unstructured":"Wei D, Sun N, Nan G, Wang Y, Liu HQ, Peeters B (2012) Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors. Hum Gene Ther 23:700\u2013710","journal-title":"Hum Gene Ther"},{"key":"3411_CR45","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/cgt.2008.31","volume":"15","author":"B Yaacov","year":"2008","unstructured":"Yaacov B, Eliahoo E, Lazar I, Ben-Shlomo M, Greenbaum I, Panet A, Zakay-Rones Z (2008) Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors. Cancer Gene Ther 15:795\u2013807","journal-title":"Cancer Gene Ther"},{"key":"3411_CR46","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.3892\/ol.2014.2562","volume":"8","author":"Y Yan","year":"2014","unstructured":"Yan Y, Jia L, Zhang J, Liu Y, Bu X (2014) Effect of recombinant Newcastle disease virus transfection on lung adenocarcinoma A549 cells in vivo. Oncol Lett 8:2569\u20132576","journal-title":"Oncol Lett"},{"key":"3411_CR47","first-page":"74","volume":"6","author":"KS Zaher","year":"2013","unstructured":"Zaher KS, El-Zahed HM, Amin AH (2013) In-vivo and In-vitro oncolytic effect of Newcastle disease virus. Acad J Cancer Res 6:74\u201378","journal-title":"Acad J Cancer Res"},{"key":"3411_CR48","doi-asserted-by":"crossref","unstructured":"Zamarin D, Holmgaard RB, Subudhi, SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP (2014) Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med 6(226):226ra32. (http:\/\/stm.sciencemag.org\/content\/6\/226\/226ra32.long)","DOI":"10.1126\/scitranslmed.3008095"},{"key":"3411_CR49","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2217\/fmb.12.4","volume":"7","author":"D Zamarin","year":"2012","unstructured":"Zamarin D, Palese P (2012) Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Fut Microbiol 7:347\u2013367","journal-title":"Fut Microbiol"}],"container-title":["Archives of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00705-017-3411-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-017-3411-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-017-3411-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T16:41:22Z","timestamp":1684860082000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00705-017-3411-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,3]]},"references-count":49,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["3411"],"URL":"https:\/\/doi.org\/10.1007\/s00705-017-3411-4","relation":{},"ISSN":["0304-8608","1432-8798"],"issn-type":[{"value":"0304-8608","type":"print"},{"value":"1432-8798","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,3]]},"assertion":[{"value":"9 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study was funded by the Government of Gujarat\u2019s program entitled \u201cStrengthening the Vanbandhu College of Veterinary Science and Animal Husbandry, Navsari phase\u2013V\u201d (Budget Head, 12404) and Zydus Research Centre, Ahmadabad.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors declare that there lies no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All applicable guidelines were followed regarding housing, care and animal experimentation during the study. Necessary prior permission was obtained from institutional ethics committee of Vanbandhu College of Veterinary Science and animal husbandry, Navsari (No-013-VCN-VMC-2014) and Zydus Research Centre, Ahmadabad (No-ZRC\/PH\/BP\/002\/12-2K14) to carry out animal experiments.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}